Clonidine Hydrochloride

Clonidine, sold under the brand name Catapres among others, is an α_2A-adrenergic receptor agonist medication used to treat high blood pressure, attention deficit hyperactivity disorder (ADHD), drug withdrawal (e.g., alcohol, opioids, or nicotine), menopausal flushing, diarrhea, spasticity, and certain pain conditions. The drug is often prescribed off-label for tics. It is used orally (by mouth), by injection, or as a transdermal skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours.

Common side effects include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur, such as a dangerous rise in blood pressure. Use during pregnancy or breastfeeding is not recommended. Clonidine lowers blood pressure by stimulating α₂-adrenergic receptors in the brain, which results in relaxation of many arteries.

Clonidine was patented in 1961 and came into medical use in 1966. It is available as a generic medication. In 2022, it was the 71st most commonly prescribed medication in the United States, with more than 9million prescriptions.

Medical uses

Clonidine is used to treat high blood pressure, attention deficit hyperactivity disorder (ADHD); drug withdrawal, including from (alcohol, opioids, and/or nicotine); menopausal flushing, diarrhea, and certain pain conditions. In addition, it also sees some use off-label for episodic insomnia, and tics (e.g. from Tourette Syndrome, restless legs syndrome, and anxiety, among others).

Resistant hypertension

Clonidine may be effective for lowering blood pressure in people with resistant hypertension.

Clonidine works by slowing the pulse rate and exerts a reduction of serum concentrations of renin, aldosterone, and catecholamines.

Uses

Borderline personality disorder

Clonidine has been studied off-label in borderline personality disorder (BPD) to address specific acute symptoms such as hyperarousal, inner tension, dissociation, self-injurious urges, and sleep disturbances.

A pilot study administering oral clonidine (75–150 μg) to 14 female BPD patients demonstrated rapid decreases in aversive inner tension, dissociative symptoms, urges to self-harm, and suicidal ideation—typically peaking within 30–60 minutes of dosing.

In a double-blind, placebo-controlled crossover trial involving 18 patients (with and without comorbid PTSD), clonidine significantly reduced hyperarousal symptoms measured by the Clinician-Administered PTSD Scale (P = 0.003), irrespective of PTSD diagnosis. It also notably improved subjective sleep latency (P = 0.005) and restorative sleep quality (P = 0.014).

A systematic review of psychopharmacology in BPD identified clonidine as a promising adjunctive therapy targeting noradrenergic dysregulation, especially in comorbid PTSD cases. However, it emphasized the limitations of small sample sizes and called for larger placebo-controlled trials.

Clinicians often employ clonidine when BPD patients present with acute emotional dysregulation, intrusive dissociation, or insomnia. Clinical anecdotal reports and patient experiences have also highlighted its practical utility.

''Note: Clonidine is not FDA-approved for the treatment of borderline personality disorder. Its use in this context should be considered investigational and symptom-targeted.''

Attention deficit hyperactivity disorder

Clonidine may improve symptoms of attention deficit hyperactivity disorder in some people but causes many adverse effects and the beneficial effect is modest. In Australia, clonidine is an accepted but not approved use for ADHD by the TGA. Clonidine, along with methylphenidate, has been studied for treatment of ADHD. While not as effective as methylphenidate in treating ADHD, clonidine does offer some benefit; it can also be useful in combination with stimulant medications. Some studies show clonidine to be more sedating than guanfacine, which may be better at bedtime along with an arousing stimulant in the morning. Clonidine has been used to reduce sleep disturbances in ADHD, including to help offset stimulant-associated insomnia. Unlike stimulant medications, clonidine is regarded as having no abuse potential, and may even be used to reduce abuse of drugs including nicotine and cocaine.

In the US, only the extended-release form of clonidine is approved for ADHD treatment.

Drug withdrawal

Clonidine may be used to ease drug withdrawal symptoms associated with abruptly stopping the long-term use of opioids, alcohol, benzodiazepines, and nicotine. It can alleviate opioid withdrawal symptoms by reducing the sympathetic nervous system response such as tachycardia and hypertension, hyperhidrosis (excessive sweating), hot and cold flashes, and akathisia. It may also be helpful in aiding smokers to quit. The sedation effect can also be useful. Clonidine may also reduce severity of neonatal abstinence syndrome in infants born to mothers that are using certain drugs, particularly opioids. In infants with neonatal withdrawal syndrome, clonidine may improve the neonatal intensive care unit Network Neurobehavioral Score.

Clonidine has also been suggested as a treatment for rare instances of dexmedetomidine withdrawal.

Spasticity

Clonidine has some role in the treatment of spasticity caused by spinal cord injury, acting principally by inhibiting excessive sensory transmission Its use, however, is mainly as a second or third line agent, due to side effects such as hypotension, bradycardia, and drowsiness. Clonidine can be administered intrathecally, which confers various benefits, including a reduction or prevention of the blood pressure lowering effects and increased effectiveness against spasticity. The effectiveness of intrathecal clonidine is comparable to that of intrathecal baclofen for spasticity.

Clonidine suppression test

The reduction in circulating norepinephrine by clonidine was used in the past as an investigatory test for phaeochromocytoma, which is a catecholamine-synthesizing tumor, usually found in the adrenal medulla. In a clonidine suppression test, plasma catecholamine levels are measured before and 3 hours after a 0.3 mg oral test dose has been given to the patient. A positive test occurs if there is no decrease in plasma levels.

Other uses

Clonidine also has several off-label uses, and has been prescribed to treat psychiatric disorders including stress, hyperarousal caused by post-traumatic stress disorder, borderline personality disorder, and other anxiety disorders. Clonidine is also a mild sedative, and can be used as premedication before surgery or procedures. It has also been studied as a way to calm acute manic episodes. Its epidural use for pain during heart attack, and postoperative and intractable pain has also been studied extensively. Clonidine can be used in restless legs syndrome. It can also be used to treat facial flushing and redness associated with rosacea. It has also been successfully used topically in a clinical trial as a treatment for diabetic neuropathy. Clonidine can also be used for migraine headaches and hot flashes associated with menopause. Clonidine has also been used to treat refractory diarrhea associated with irritable bowel syndrome, fecal incontinence, diabetes, diarrhea associated with opioid withdrawal, intestinal failure, neuroendocrine tumors, and cholera. Clonidine can be used in the treatment of Tourette syndrome (specifically for tics). Clonidine has also had some success in clinical trials for helping to remove or ameliorate the symptoms of hallucinogen persisting perception disorder (HPPD).

Injection of α₂-adrenergic receptor agonists into the knee joint space, including clonidine, may reduce the severity of knee pain after arthroscopic knee surgery.

Light-activated derivatives of clonidine (adrenoswitches) have been developed for research purposes and shown to control pupillary reflex with light in blind mice by topical application.

Pregnancy and breastfeeding

It is classified by the TGA of Australia as pregnancy category B3, which means that it has shown some detrimental effects on fetal development in animal studies, although the relevance of this to human beings is unknown. Clonidine appears in high concentration in breast milk; a nursing infant's serum clonidine concentration is approximately 2/3 of the mother's. Caution is warranted in women who are pregnant, planning to become pregnant, or are breastfeeding.

Adverse effects

The principal adverse effects of clonidine are sedation, dry mouth, and hypotension (low blood pressure).

By frequency

Very common (>10% frequency):

* Dizziness
* Orthostatic hypotension
* Somnolence (dose-dependent)
* Dry mouth
* Headache (dose-dependent)
* Fatigue
* Skin reactions (if given transdermally)
* Hypotension

Common (1–10% frequency):

* Anxiety
* Constipation
* Sedation (dose-dependent)
* Nausea/vomiting
* Malaise
* Abnormal LFTs
* Rash
* Weight gain/loss
* Pain below the ear (from salivary gland)
* Erectile dysfunction

Uncommon (0.1–1% frequency):

* Delusional perception
* Hallucination
* Nightmare
* Paresthesia
* Sinus bradycardia
* Raynaud's phenomenon
* Pruritus
* Urticaria

Rare (<0.1% frequency):

* Gynaecomastia
* Impaired ability to cry
* Atrioventricular block
* Nasal dryness
* Colonic pseudo-obstruction
* Alopecia
* Hyperglycemia

Withdrawal

Because clonidine suppresses sympathetic outflow, resulting in lower blood pressure, sudden discontinuation can result in acute hypertension due to a rebound in sympathetic outflow. In extreme cases, this can result in a hypertensive crisis, which is a medical emergency.

Clonidine therapy should generally be gradually tapered when discontinuing therapy to avoid rebound effects from occurring. Treatment of clonidine withdrawal hypertension depends on the severity of the condition. Reintroduction of clonidine for mild cases, alpha and beta blockers for more urgent situations. Beta blockers should never be used alone to treat clonidine withdrawal as alpha vasoconstriction would still continue.

Pharmacology

Mechanism of action

Clonidine crosses the blood–brain barrier.

High blood pressure

Clonidine treats high blood pressure by stimulating α₂ receptors in the brainstem, which decreases peripheral vascular resistance, lowering blood pressure. It has specificity towards the presynaptic α₂ receptors in the vasomotor center in the brainstem. This binding has a sympatholytic effect, suppresses release of norepinephrine, ATP, renin, and neuropeptide Y which if released would increase vascular resistance.

Clonidine also acts as an agonist at imidazoline-1 (I₁) receptors in the brain, and it is hypothesized that this effect may contribute to reducing blood pressure by reducing signaling in the sympathetic nervous system; this effect acts upstream of the central α₂ agonist effect of clonidine.

Clonidine may also cause bradycardia, theoretically by increasing signaling through the vagus nerve. When given intravenously, clonidine can temporarily increase blood pressure by stimulating α₁ receptors in smooth muscles in blood vessels. This hypertensive effect is not usual when clonidine is given orally or by the transdermal route.

Plasma concentration of clonidine exceeding 2.0 ng/mL does not provide further blood pressure reduction.

Attention deficit hyperactivity disorder

In the setting of attention deficit hyperactivity disorder (ADHD), clonidine's molecular mechanism of action occurs due to its agonism at the α_2A adrenergic receptor, the subtype of the adrenergic receptor that is most principally found in the brain. Within the brain, the α_2A adrenergic receptors are found within the prefrontal cortex (PFC), among other areas. The α_2A adrenergic receptors are found on the presynaptic cleft of a given neuron, and, when activated by an agonist, the effect on downstream neurons is inhibitory. The inhibition is accomplished by preventing the secretion of the neurotransmitter norepinephrine. Thus, clonidine's agonism on α_2A adrenergic receptors in the PFC inhibits the action of downstream neurons by preventing the secretion of norepinephrine.

This mechanism is similar to the brain's physiological inhibition of PFC neurons by the locus ceruleus (LC), which secretes norepinephrine into the PFC. Although norepinephrine can also bind to target adrenergic receptors on the downstream neuron (otherwise inducing a stimulatory effect), norepinephrine also binds to α_2A adrenergic receptors (akin to clonidine's mechanism of action), inhibiting the release of norepinephrine by that neuron and inducing an inhibitory effect. Because the PFC is required for working memory and attention, it is thought that clonidine's inhibition of PFC neurons helps to eliminate irrelevant attention (and subsequent behaviors), improving the person's focus and correcting deficits in attention.

Growth hormone test

Clonidine stimulates release of GHRH hormone from the hypothalamus, which in turn stimulates pituitary release of growth hormone. This effect has been used as part of a "growth hormone test," which can assist with diagnosing growth hormone deficiency in children.

Pharmacokinetics

After being ingested, clonidine is absorbed into the blood stream rapidly with an overall bioavailability around 70–80%. Peak concentrations in human plasma occur within 60–90 minutes for the "immediate release" (IR) version of the drug, which is shorter than the "extended release" (ER/XR) version. Clonidine is fairly lipid soluble with the logarithm of its partition coefficient (log P) equal to 1.6; to compare, the optimal log P to allow a drug that is active in the human central nervous system to penetrate the blood brain barrier is 2.0. Less than half of the absorbed portion of an orally administered dose will be metabolized by the liver into inactive metabolites, with roughly the other half being excreted unchanged by the kidneys. About one-fifth of an oral dose will not be absorbed, and is thus excreted in the feces. Work with liver microsomes shows in the liver clonidine is primarily metabolized by CYP2D6 (66%), CYP1A2 (10–20%), and CYP3A (0–20%) with negligible contributions from the less abundant enzymes CYP3A5, CYP1A1, and CYP3A4. 4-hydroxyclonidine, the main metabolite of clonidine, is also an α_2A agonist but is non lipophilic and is not believed to contribute to the effects of clonidine since it does not cross the blood–brain barrier.

Measurements of the half-life of clonidine vary widely, between 6 and 23 hours, with the half-life being greatly affected by and prolonged in the setting of poor kidney function. Variations in half-life may be partially attributable to CYP2D6 genetics. Some research has suggested the half-life of clonidine is dose dependent and approximately doubles upon chronic dosing, while other work contradicts this. Following a 0.3 mg oral dose, a small study of five patients by Dollery et al. (1976) found half-lives ranging between 6.3 and 23.4 hours (mean 12.7). A similar N=5 study by Davies et al. (1977) found a narrower range of half-lives, between 6.7 and 13 hours (mean 8.6), while an N=8 study by Keraäen et al. that included younger patients found a somewhat shorter mean half-life of 7.5 hours.

History

Clonidine was introduced in 1966. It was first used as a hypertension treatment under the trade name of Catapres.

Society and culture

Brand names

As of June 2017, clonidine is marketed under many brand names worldwide: Arkamin, Aruclonin, Atensina, Catapin, Catapres, Catapresan, Catapressan, Chianda, Chlofazoline, Chlophazolin, Clonid-Ophtal, Clonidin, Clonidina, Clonidinã, Clonidine, Clonidine hydrochloride, Clonidinhydrochlorid, Clonidini, Clonidinum, Clonigen, Clonistada, Clonnirit, Clophelinum, Dixarit, Duraclon, Edolglau, Haemiton, Hypodine, Hypolax, Iporel, Isoglaucon, Jenloga, Kapvay, Klofelino, Kochaniin, Lonid, Melzin, Menograine, Normopresan, Paracefan, Pinsanidine, Run Rui, and Winpress. It is marketed as a combination drug with chlortalidone as Arkamin-H, Bemplas, Catapres-DIU, and Clorpres, and in combination with bendroflumethiazide as Pertenso.

References

External links

* Alpha-2 agonists i
ADHD

{{Authority control

Alpha-2 adrenergic receptor agonists
Anilines
Antihypertensive agents
Antimigraine drugs
Anxiolytics
Appetite stimulants
Attention deficit hyperactivity disorder management
Chlorobenzene derivatives
Drugs developed by Boehringer Ingelheim
Drugs developed by Novartis
Guanidines
Imidazoline receptor modulators
Imidazolines
Ophthalmology drugs
Wikipedia medicine articles ready to translate
Products introduced in 1961